On November 12, GeneDx Holdings fell 5.03% in Regular Trading, trading at $52.46 per share, with turnover of $4.4317 million.
The clearest catalyst in recent public disclosures was continued pressure after the company issued cautious forward guidance alongside its latest quarterly report, even though adjusted earnings and revenue both edged past consensus estimates.
GeneDx Holdings reported adjusted EPS of $0.28 for the September quarter, above the $0.07 consensus, on revenue of $123.1 million versus expectations of $122.9 million. However, Q4 revenue guidance of $135 million came in below the $142.6 million consensus, while the company reiterated full-year revenue guidance of $475 million to $490 million rather than raising it. Post-results, Piper Sandler maintained a Buy rating with a $95 target, while BTIG kept Buy but cut its target to $85 from $90, indicating a more cautious view on near-term growth cadence.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments